Compare Ginkgo Bioworks Holdings Inc (DNA) vs RLX Technology Inc (RLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs RLX Technology Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $7.42 (market cap $505.73M), while RLX Technology Inc trades at $2.02 (market cap $2.42B). The key difference: RLX Technology Inc is far larger — about 4.8× Ginkgo Bioworks Holdings Inc's market cap, and RLX Technology Inc pays a 5.05% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | RLX | |
|---|---|---|
Market Cap | $505.73M | $2.42B |
Sector | Health | Technology |
52-Week High | $16.14 | $2.73 |
52-Week Low | $5.48 | $1.79 |
Enterprise Value | $607.68M | $1.04B |
Dividend Yield | — | 5.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $7.29, down 4.71% with bearish technical signals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, continuing its strategic pivot to autonomous labs. Despite beating EPS expectations in two of the last three quarters, DNA shows negative profitability with -219.6% net income margin and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant institutional selling pressure.
DNA faces substantial execution risk during its business transition, with declining revenue and persistent losses offset by potential in autonomous laboratory technology. The stock's current valuation at 3.61x sales appears stretched given negative earnings, requiring successful operational turnaround for sustainable recovery. Near-term catalysts depend on revenue stabilization and cost management improvements.
RLX trades at $2.01, up 0.5% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported Q1 2026 revenue growth driven by international expansion, with a net income margin of 22.47% in 2026. Recent news highlights its Q2 2026 earnings call scheduled for August 14, 2026, focusing on European integration.
The outlook is mixed: strong international revenue growth and solid profitability support upside, but consecutive earnings misses and a single analyst's hold rating indicate caution. Key risks include regulatory scrutiny in the vaping industry and execution challenges in global markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →
